Why the study?
Does enhanced IPV (eIPV) reduce the excretion of poliovirus compared to OPV alone in children?
Does enhanced IPV (eIPV) reduce the excretion of poliovirus compared to OPV alone in children?
Two doses of enhanced IPV partially protect against poliovirus shedding, suggesting that IPV-vaccinated communities have some protection from the spread of poliovirus.
Suggests partial community protection from poliovirus spread with IPV; leaves open confirmation in randomized transmission studies.
Inactivated poliovirus vaccine (IPV) is believed to induce significantly lower mucosal immunity than oral poliovirus vaccine (OPV). Most of the data supporting this were generated before enhanced IPV (eIPV) was introduced. Excretion of poliovirus by OPV recipients can be used to assess intestinal immunity. We studied polymerase chain reaction amplification of viral complementary DNA from the stool of children vaccinated with either OPV alone or eIPV. Of first-time OPV recipients, 92% excreted virus after 1 week, and 81% excreted virus after 3 weeks. Prior vaccination with OPV reduced the number to 22% and shortened the duration of virus excretion (to 5% after 3 weeks). Two doses of IPV reduced the number of poliovirus-positive 1-week samples (to 76%), the duration of shedding (to 37% at 3 weeks), and the quantity of excreted virus. This suggests that IPV-vaccinated communities are partially protected from the spread of poliovirus. Further enhancement of IPV potency may lead to even higher levels of mucosal immunity.
No takes yet. Share an insight, caveat, or question.
Laassri et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: